Product/Composition:- | Rasburicase Injection |
---|---|
Strength:- | 7.5 mg/15 mL vial |
Form:- | IV infusion |
Reference Brands:- | Elitek(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Rasburicase Injection 7.5 mg/15 mL is used to treat tumor lysis syndrome (TLS) in cancer patients, particularly those with leukemia and lymphoma. Available in both the U.S. and EU, it helps prevent kidney damage by converting uric acid into allantoin. Essential for oncology B2B distribution.
Rasburicase Injection 7.5 mg/15 mL is a critical treatment for tumor lysis syndrome (TLS), commonly associated with hematologic cancers like leukemia and lymphoma. By converting uric acid into allantoin, Rasburicase reduces the risk of kidney damage caused by high uric acid levels. Approved in both the U.S. and EU, Elitek (brand name in the U.S.) is supplied as a sterile IV solution for infusion. Rasburicase is essential for B2B pharmaceutical distribution, supporting oncology care centers, hospitals, and clinics with essential treatment for high-risk cancer patients undergoing chemotherapy.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications